RXi Pharma in-licenses targeted vaccine for gynecological cancers
US biotech firm RXi Pharmaceuticals (Nasdaq: RXII) has licensed worldwide rights to develop and commercialize a folate binding protein-E39 (FBP) targeted vaccine to prevent recurrence in gynecological cancers such as ovarian and endometrial adenocarcinomas from the University of Texas M D Anderson Cancer Center and Henry M Jackson Foundation for the Advancement of Military Medicine. Financial terms of the accord were not disclosed.
FBP has been granted Investigational New Drug approval by the US Food and Drug Administration to enter clinical trials. Institutional Review Board (IRB) approval has also been received allowing RXi to initiate Phase I trials by the end of 2011, the company noted. The new license doubles RXi's oncology pipeline which includes NeuVax (E75), scheduled to commence its Phase III PRESENT study in breast cancer in the first half of 2012.
Ph I trials expected to start this year
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze